tbuckley/cabot-search huggingface dataset:
The Bacteriophage: Its Rôle in Immunity.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dynamic metal-thiolate cluster structure of metallothioneins.
Authors: M Vasák
Journal: Environmental Health Perspectives (1986)

113Cd-NMR studies have established that vertebrate and invertebrate metallothioneins contain two unique metal-thiolate clusters. However, it proved to be difficult to account theoretically for all features of the 113Cd-NMR spectra. In a reinvestigation of these features using chromatographically homogeneous 113Cd7-metallothionein we have identified a total of seven 113Cd resonances and have confirmed the massive intensity difference among these signals. From the effects of variations in temperature, ionic strength, and magnetic field on one-dimensional 113Cd-NMR spectra and from two-dimensional J-resolved 113Cd-NMR spectrum it was concluded that the seven 113Cd signals are composed of several overlapping multiplets and indicative of a dynamic organization of the metal-thiolate clusters. The same nonrigid structure is also indicated individually by recent two-dimensional correlated (COSY) 1H-NMR studies of 113Cd7-metallothionein. While showing 113Cd-1H coupling for 19 of the 20 cysteine residues, these studies have evidence for only two
"MELLON ISSUES BEER REGULATIONS"
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The natural history and epidemiology of diabetic nephropathy. Implications for prevention and control
Authors: J. V. Selby
Journal: JAMA (1990)

PERSONS with diabetes are at increased risk for several types of kidney disease,<sup>1</sup>but the predominant cause of end-stage renal disease (ESRD) in this disorder is diabetic nephropathy—a complication unique to diabetes. Since the initiation of Medicare coverage for treatment of ESRD in 1972, the proportion of new ESRD cases attributed to diabetic nephropathy has increased from approximately 10% in 1973<sup>2</sup>to 30% in 1987.<sup>3</sup>Diabetes is now the single most frequent reason for beginning treatment of ESRD, with 10 025 new cases caused by diabetic nephropathy in 1987.<sup>3</sup> In this article, we review the natural history and epidemiology of diabetic nephropathy and the evidence for efficacy of preventive and therapeutic measures. From this review, a strategy for preventing and controlling this important cause of morbidity is outlined. <h3>NATURAL HISTORY OF DIABETIC KIDNEY DISEASE</h3> <i>Diabetic nephropathy</i>is currently defined by the presence of a persistently positive
Exercise-associated urinary incontinence
Authors: J. M. Thorp
Journal: JAMA (1991)

<h3>To the Editor.—</h3> The patient with exercise-associated urinary incontinence presented in the Questions and Answers section of the January 23, 1991, issue of<i>JAMA</i>could well have another source for her perineal wetness than that mentioned by the consultants.<sup>1</sup>Her symptomless onset of perineal wetness occurring solely in the periovulatory portion of her cycle might well be cervical mucus under the influence of estrogen. My anecdotal experience in caring for a number of women who use contraception with ovulation-prediction techniques supports such a diagnosis, as many of these patients report copious passage of mucus with exercise. Interestingly enough, this seems to be a complaint limited to parous women and has its onset after the cessation of lactation when ovulation resumes. My hypothesis could be easily tested by having the patient wear a perineal pad in the periovulatory period while exercising. Close inspection would allow differentiation between mucus and urine
15. Diabetes Advocacy: <i>Standards of Medical Care in Diabetes—2018</i>
Journal: Diabetes Care (2017)

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Diffuse hypertrichosis during treatment with 5% topical minoxidil
Authors: A.M. PELUSO, C. MISCIALI, C. VINCENZI, A. TOSTI
Journal: British Journal of Dermatology (1997)

Five women affected by androgenetic alopecia developed severe hypertrichosis of the face and limbs after 2‐3 months of treatment with 5% topical minoxidil. Minoxidil was discontinued and in all patients the hypertrichosis disappeared from the face and arms after 1‐3 months, and from legs after 4‐5 months. Systemic absorption of minoxidil, and a high sensitivity to minoxidil of the follicular apparatus in these areas, is hypothesized.
PDTB-21. CD271 (p75NTR) AS A NOVEL DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR SHH MEDULLOBLASTOMA
Authors: Lisa Liang, Ludivine Coudiere-Morrision, Nazanin Tatari, Marc Remke, Vijay Ramaswamy, Magimairajan Issaivanan, Timothy Ryken, Marc Del Bigio, Michael Taylor, Tamra Werbowetski-Ogilvie
Journal: Neuro-Oncology (2016)

Medulloblastoma (MB) is the most common malignant primary brain tumor in children. Despite improved clinical outcomes, children with MB often suffer from consequences of treatment such as surgery, chemotherapy and radiation. MB is currently classified into 4 distinct molecular subtypes based on genomic alterations, gene expression profiles, response to treatment and cell of origin; WNT, SHH, Group 3, and Group 4. This extensive heterogeneity has revealed a critical need for subtype-specific, functionally validated biomarkers and therapeutic strategies. Using an unbiased high throughput flow cytometry screen, we identified CD271/p75NTR as a candidate SHH stem/progenitor cell marker. Here, we explored the functional role of CD271 in SHH MB cell lines and primary cultures, using gain/loss of function studies and treatments with a CD271 inhibitor, γ-secretase inhibitor (GSI). This was followed by cellular assays to measure sphere-forming capacity, self-renewal, proliferation and differentiation. Immunohistochemical (IHC) staining for CD271 was also conducted in formalin fixed paraffin embedded (FFPE) patient samples to assess expression of CD271 across MB subtypes. CD271 levels were high in SHH MB samples with minimal to no staining in WNT, Group 3, and Group 4 MBs. Stable overexpression of CD271 resulted in increased tumorsphere size, whereas CD271 knockdown cells exhibited a reversal of this cellular phenotype. Similarly, treatment of UI226 SHH MB primary cells with GSI also resulted in a significant decrease in tumorsphere growth and self-renewal, providing an opportunity to exploit CD271 as a therapeutic target. As CD271 appears to be specific to SHH MB, this marker may serve as a potential diagnostic tool. Further characterization of CD271 signaling in SHH MB could ultimately lead to development of targeted therapies that will lessen the broad impact of current toxic treatments, and improve the quality of life for children who survive long- term.
In Vitro Estrogenicity of Polybrominated Diphenyl Ethers, Hydroxylated PBDEs, and Polybrominated Bisphenol A Compounds
Authors: Ilonka A. T. M. Meerts, Robert J. Letcher, Saske Hoving, Goran Marsh, Ake Bergman, Josephine G. Lemmen, Bart van der Burg, Abraham Brouwer
Journal: Environmental Health Perspectives (2001)

Polybrominated diphenyl ethers (PBDEs) are used in large quantities as additive flame retardants in plastics and textile materials. PBDEs are persistent compounds and have been detected in wildlife and in human adipose tissue and plasma samples. In this study, we investigated the (anti)estrogenic potencies of several PBDE congeners, three hydroxylated PBDEs (HO-PBDEs), and differently brominated bisphenol A compounds in three different cell line assays based on estrogen receptor (ER)-dependent luciferase reporter gene expression. In human T47D breast cancer cells stably transfected with an estrogen-responsive luciferase reporter gene construct (pEREtata-Luc), 11 PBDEs showed estrogenic potencies, with concentrations leading to 50% induction (EC(50)) varying from 2.5 to 7.3 microM. The luciferase induction of the most potent HO-PBDE [2-bromo-4-(2,4,6-tribromophenoxy)phenol] exceeded that of estradiol (E(2)), though at concentrations 50,000 times higher. As expected, brominated bisphenol A compounds with the lowest degree of bromination showed highest estrogenic potencies (EC(50) values of 0.5 microM for 3-monobromobisphenol A). In an ER alpha-specific, stably transfected human embryonic kidney cell line (293-ER alpha-Luc), the HO-PBDE 4-(2,4,6-tribromophenoxy)phenol was a highly potent estrogen with an EC(50) < 0.1 microM and a maximum 35- to 40-fold induction, which was similar to E(2). In an analogous ER beta-specific 293-ER betas-Luc cell line, the agonistic potency of the 4-(2,4,6-tribromophenoxy)phenol was much lower (maximum 50% induction compared to E(2)), but EC(50) values were comparable. These results indicate that several pure PBDE congeners, but especially HO-PBDEs and brominated bisphenol A-analogs, are agonists of both ER alpha and ER beta receptors, thus stimulating ER-mediated luciferase induction in vitro. These data also suggest that in vivo metabolism of PBDEs may produce more potent pseudoestrogens.
THE SPECIFIC TREATMENT OF HAY FEVER.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Activin induces cell death in hepatocytesin vivo andin vitro
Authors: Ralph H. Schwall, Kim Robbins, Paula Jardieu, Ling Chang, Cora La, Timothy G. Terrel
Journal: Hepatology (1993)

While studying endocrine responses to activin in female rats, we discovered that activin caused a marked reduction in liver mass. The regressed livers exhibited no gross signs of necrosis or infarction, but histopathological evaluation revealed extensive cell death in the centrilobular regions. The dying cells appeared to fragment into structures resembling apoptotic bodies. Liver mass and histological appearance were restored after cessation of activin infusion, indicating that on an organ level, this effect was reversible. To determine whether the effects observed in vivo were caused by direct actions on the liver, we then tested activin on isolated hepatocytes in serum-free medium. Under these conditions, activin caused many hepatocytes to undergo fragmentation, which was accompanied by a loss of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-reducing activity, an index of viability. We compared the effects of activin with those of transforming growth factor-β because activin is structurally related to transforming growth factor-β and because transforming growth factor-β has been shown previously to induce cell death in hepatocytes. Both proteins caused cell death of comparable magnitude, as defined by the extent of loss of MTT-reducing activity, but transforming growth factor-β was active at one tenth of the effective activin concentrations. A neutralizing monoclonal antibody to transforming growth factor-β blocked the response to transforming growth factor-β but had no effect on the response to activin. Conversely, follistatin, an activinbinding protein, blocked the response to activin but not to transforming growth factor-β. Inhibin, which antagonizes the effects of activin in many systems, had little effect on the response to activin. Activin and transforming growth factor-β differed in their onset of action; exposure to transforming growth factor-β for only 1 hr induced a maximal response, whereas maximal response to activin required its continuous presence for 24 hr. These results show a novel effect of activin on cell death in hepatocytes in vivo and in vitro , suggesting that activin may have a previously unrecognized role in regulating hepatic function. (Hepatology 1993;18:347-356).
British Medical Journal, London
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lymphomatoid granulomatosis presenting as fever of unknown origin
Authors: C. C. Yockey
Journal: JAMA (1977)

IN 1972, Liebow et al<sup>1</sup>published a description of lymphomatoid granulomatosis (LYG), an angiocentric and angiodestructive lymphoreticular proliferative disorder that predominantly involves the lungs. We report a case that presented in a manner not previously described in literature. <h3>Report of a Case</h3> A 26-year-old man was admitted to USAF Hospital, Bitburg, Germany, on July 1, 1974, with complaints of fever, ataxia, diplopia, and a 4.5 kg weight-loss over a three-month period. On physical examination his body temperature was 38.3 °C orally. Axillary and inguinal adenopathy, hepatosplenomegaly, hyperactive deep tendon reflexes, ankle clonus, and Babinski's sign were present. Auscultation and percussion of the chest were unremarkable as was the chest roentgenogram. Hematocrit, alkaline phosphatase, creatinine phosphokinase (CPK), and total bilirubin levels were normal. Total WBC count ranged from 1,400 to 3,100/cu mm. Contrast roentgenogram of the upper gastrointestinal tract, SGOT, EEG, and biopsy specimens of the liver and right inguinal
House staff organizations and their demands. A threat to medical education?
Authors: S. S. Bergen
Journal: JAMA (1970)

A movement is developing among house staff members to organize into groups with the purpose of changing the health-care system. Unfortunately, despite this commendable and long over-due stance, at least one of these organizations has taken on the appearance of a labor union (<i>Hospital Physician</i>, April 1966, p 78). Although referred to as a committee it is a union and many of its practices are indistinguishable from those of any other union. What has made our house staff officers choose this path of action? What has forced the young physician of today to become an activist working against the system? We are at fault. For years we have been aware and have personally experienced many of the wrongs in the educational and service systems of health care which lead to the development of a physician. We have failed to assume our proper role, that of demanding improvement. We have accepted
Antiemesis
Authors: David S. Ettinger, Debra K. Armstrong, Sally Barbour, Michael J. Berger, Philip J. Bierman, Bob Bradbury, Georgianna Ellis, Steve Kirkegaard, Dwight D. Kloth, Mark G. Kris, Dean Lim, Laura Boehnke Michaud, Lida Nabati, Kim Noonan, Hope S. Rugo, Darby Siler, Steven M. Sorscher, Sundae Stelts, Lisa Stucky-Marshall, Barbara Todaro, Susan G. Urba
Journal: Journal of the National Comprehensive Cancer Network (2012)

OverviewChemotherapy-induced (or radiotherapy-induced) vomiting (emesis) and nausea can significantly affect a patient's quality of life, leading to poor compliance with further chemotherapy or radiation therapy treatment.][3][4] The incidence and severity of nausea and/or vomiting in patients receiving chemotherapy or radiation therapy (or both) are affected by numerous factors, including 1) specific chemotherapeutic agents used; 2) dosage of the agents; 3) schedule and route
Avalanche!
Authors: Peachy Ridgeway Gilmer
Journal: JAMA (1983)

I think that putting the latest Agenda Book on the top of the pile triggered it. I swung around in my chair, and scores of books and journals started slipping over the telephone and down the side of the desk, submerging me on the floor, pinned between the wastebasket and the wall. The avalanche had struck. Visitors often peered past me and quietly pondered the piles stacked on the table at my elbow. Some even murmured admiration at the accumulation of materia medica. Yet, no one had forewarned me of the price of prolonged procrastination. Oh, retrospectively, there had been minor slips and tremors as the drifts accumulated deeper and deeper. But I had always been able to steady them with a reassuring reshuffle and the resolution that I would get back to them soon. Now it was too late. Gingerly, I extricated my head and shoulders out from under
Career prospects in Dermatology in the U.K.
Journal: British Journal of Dermatology (1987)

British Journal of DermatologyVolume 116, Issue 2 p. 284-285 Career prospects in Dermatology in the U.K. First published: February 1987 https://doi.org/10.1111/j.1365-2133.1987.tb05838.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Volume116, Issue2February 1987Pages 284-285 RelatedInformation
Selected measures of health status for Mexican-American, mainland Puerto Rican, and Cuban-American children
Authors: F. S. Mendoza
Journal: JAMA (1991)

The 1987 National Vital Statistics System and the Hispanic Health and Nutrition Examination Survey (1982 through 1984) were used to assess the health status of Mexican-American, mainland Puerto Rican, and Cuban-American children by examining the prevalences of pregnancy outcomes and chronic medical conditions. The low—birth-weight rate among Hispanics (7.0%) compared favorably with that of non-Hispanic whites (7.1%) despite the greater poverty and lower levels of education among Hispanics. When examined by Hispanic subgroup, however, significant differences were present, with mainland Puerto Ricans having the highest prevalences of low—birth-weight infants. Premature births were more common among all three Hispanic subgroups than among non-Hispanic whites. Mexican-American and Cuban-American children had a similar prevalence of (3.9% and 2.5%, respectively) chronic medical conditions compared with non-Hispanic white children; Puerto Rican children had a higher prevalence of chronic medical conditions (6.2%). When assessed by these health status indicators, Hispanic children seem to have a health status similar to non-Hispanic white children. However, mainland Puerto Rican children seem at greater risk for poor health, reflecting the US Hispanic population's heterogeneity. Health programs targeted at US Hispanics should appropriately consider these group differences. (<i>JAMA</i>. 1991;265:227-232)